Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

HanAll's Partner HBM Initiates Phase 3 of Batoclimab in gMG in China

Date|2021-09-28

Related Data

HanAll Biopharma (KRX: 009420.KS) today announced that its partner Harbour BioMed has commenced the first dosing of Phase 3 of batoclimab in patients with generalized myasthenia gravis (gMG)​ in China. ​

 

For more information, please refer to the link below. 

- HBM press release link: https://www.harbourbiomed.com/news/167.html​​

​ 

NextHanAll's Partner HBM Completes First Dosing of Phase 2 of Batoclimab in TED in China

PrevHanAll's Partner HBM Announces IND Approval for Phase 2 of Batoclimab in CIDP in China

List